Azitra Inc. AZTR 深 沪
等待开盘 09-17 09:30:00 美东时间
0.80
-0.004
-0.50%
华盛通- 最 高0.8151
- 今 开0.782
- 成交量 16.02万股
- 最 低 0.781
- 昨 收 0.804
- 总市值 432.40万
- 52周最高 4.329
- 市盈率 静 --
- 换手率 2.96%
- 52周最低 0.7015
- 委 比 89.33%
- 总股本 540.50万
- 历史最高 1034.964
- 量 比 0.74
- 振 幅 4.24%
- 历史最低 0.781
- 每 手 1
- 风险率 17.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Azitra Stock (AZTR) Rockets on Clinical Trial Update
Azitra stock rallied on Wednesday alongside a clinical trial update.
08-27 21:25
Why Azitra Stock Shot Up 59% After-Hours?
Azitra shares surged over 58% after hours following a reverse stock split and new institutional ownership disclosure by Alumni Capital.
08-22 12:25
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen (NASDAQ:FGEN) shares rose 20.1% to $10.11 during Monday's aft...
08-12 05:06
Azitra shares are trading lower after the company announced a 1-for-6.66 reverse stock split.
Azitra shares are trading lower after the company announced a 1-for-6.66 revers...
08-12 04:38
Azitra, Inc. Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceut...
08-12 04:15
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Acurx Pharmaceuticals (NASDAQ:ACXP) stock moved upwards by 235.5% to $...
06-17 20:08
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patients have receive...
06-17 20:02
Azitra To Present Data Highlighting Phase 1/2 Clinical Trial Of ATR04-484 In EGFR Inhibitor-Associated Rash At 2025 ASCO Annual Meeting
Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical
05-28 20:38
Azitra GAAP EPS of -$0.23
Azitra press release (NYSE:AZTR): Q1 GAAP EPS of -$0.23. Cash and cash equivalents: As of March 31, 2025, the Company had cash and cash equivalents of $3.2 million. More on Azitra Azitra enters shar...
05-14 23:35
